6 Result(s)
within
C. Brambilla
Gynecology
-
Chapter and Conference Paper
Primary Chemotherapy for Resectable Breast Cancer
Primary (neoadjuvant, preoperative) chemotherapy for surgically curative breast cancer is a novel treatment approach. The sequentially combined strategy derives from prior experience achieved with locally adva...
-
Chapter and Conference Paper
Salvage Treatments in Relapsing Resectable Breast Cancer
There is convincing evidence that the natural history of resectable breast cancer can be perturbed by adjuvant medical intervention. In fact, a highly significant reduction in the recurrence rate has been docu...
-
Chapter and Conference Paper
The Milan Experience with Adjuvant Chemotherapy in Premenopausal Breast Cancer
In spite of the many scientific and clinical debates which have involved adjuvant chemotherapy for high-risk resectable breast cancer, there is general agreement that polydrug regimens, in particular, CMF (cyc...
-
Chapter
Chemotherapy of Advanced Disease
During the past 15 years, the potential of cytotoxic agents to palliate, or even cure in a few instances, metastatic breast cancer has undoubtedly reached a plateau. Despite innumerable reports dealing with pr...
-
Chapter
Adjuvant Programs for Postmenopausal Women with Node-Positive Breast Cancer:Preliminary Analysis of 5-Year Results
The results of the first CMF program (cyclophosphamide, methotrexate, and fluorouracil given for 12 monthly cycles) indicated only a slight benefit for the subgroup of postmenopausal patients with node-positiv...
-
Chapter
Relationship Between Estrogen Receptors and CMF Adjuvant Chemotherapy
The presence of estrogen receptors (ER) has been found to have prognostic significance in patients with resectable breast cancer, regardless of whether axillary nodes are positive or negative [12, 14]. Since a...
